227 related articles for article (PubMed ID: 33826052)
1. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M
J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052
[TBL] [Abstract][Full Text] [Related]
2. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
[TBL] [Abstract][Full Text] [Related]
3. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Assi R; Kantarjian H; Keating M; Pemmaraju N; Verstovsek S; Garcia-Manero G; Ravandi F; Borthakur G; Dahl J; Jabbour E; Cortes JE
Leuk Lymphoma; 2021 Apr; 62(4):909-917. PubMed ID: 33283580
[TBL] [Abstract][Full Text] [Related]
4. Managing pregnancy in chronic myeloid leukaemia.
Palani R; Milojkovic D; Apperley JF
Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
[TBL] [Abstract][Full Text] [Related]
5. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
6. Management of pregnant chronic myeloid leukemia patients.
Abruzzese E; Trawinska MM; de Fabritiis P; Baccarani M
Expert Rev Hematol; 2016 Aug; 9(8):781-91. PubMed ID: 27352939
[TBL] [Abstract][Full Text] [Related]
7. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
[No Abstract] [Full Text] [Related]
8. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
9. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcomes after assisted human reproduction.
Okun N; Sierra S; ;
J Obstet Gynaecol Can; 2014 Jan; 36(1):64-83. PubMed ID: 24444289
[TBL] [Abstract][Full Text] [Related]
11. Survey of Reproductive Experiences and Outcomes of Cancer Survivors Who Stored Reproductive Material Before Treatment.
Hammarberg K; Kirkman M; Stern C; McLachlan RI; Clarke G; Agresta F; Gook D; Rombauts L; Vollenhoven B; Fisher JRW
Hum Reprod; 2017 Dec; 32(12):2423-2430. PubMed ID: 29045667
[TBL] [Abstract][Full Text] [Related]
12. Fertility after breast cancer treatment.
Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
[TBL] [Abstract][Full Text] [Related]
13. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
14. Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α.
Gazdaru S; Perey L; Rosselet A; Mathevet P; Chalandon Y; Vulliemoz N
Oncologist; 2018 Jun; 23(6):719-721. PubMed ID: 29212733
[TBL] [Abstract][Full Text] [Related]
15. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
[TBL] [Abstract][Full Text] [Related]
17. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.
Rios SJ; Martínez-Montesinos L; Aroca C; Teruel-Montoya R; Ferrer-Marín F
J Assist Reprod Genet; 2020 Oct; 37(10):2473-2476. PubMed ID: 32766925
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
Bhattacharjee U; Jandial A; Singh C; Lekshmon KS; Mishra K; Sandal R; Nampoothiri R; Naseem S; Suri V; Jain A; Lad DP; Prakash G; Khadwal A; Malhotra P
Leuk Res; 2023 Oct; 133():107367. PubMed ID: 37566974
[TBL] [Abstract][Full Text] [Related]
19. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
20. Fertility after contraception or abortion.
Huggins GR; Cullins VE
Fertil Steril; 1990 Oct; 54(4):559-73. PubMed ID: 2209874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
